HKSE · 2251.HK
Beijing Airdoc Technology Co., Ltd.
HK$8.86-HK$0.12 (-1.28%)
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.63% below the high.
Loading market information…
HKSE · 2898.HK · HKD
Stock price
Quote as of Mar 6, 2026, 05:25 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sunho Biologics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$8.86-HK$0.12 (-1.28%)
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.63% below the high.
HK$0.89-HK$0.01 (-0.56%)
Kindstar Globalgene Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
HK$0.98+HK$0.01 (+1.03%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.42% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$2.52+HK$0.01 (+0.2%)
3D Medicines Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
HK$4.13HK$0.00 (0.0%)
Sirnaomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.47% below the high.
HK$0.98HK$0.00 (0.0%)
Venus Medtech (Hangzhou) Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.61% below the high.
HK$0.58+HK$0.05 (+8.41%)
Broncus Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 78.91% below the high.
